Last edition
News about "Iksuda Therapeutics"
Iksuda Therapeutics Secures US FDA IND Clearance for Novel ADC Candidate IKS04 in GI Cancers
Phase 1 trial to evaluate first-of-its-kind CA242-targeted antibody-drug conjugate with an innovative co-administration regimen designed to improve solid tumour penetration and therapeutic efficacy.
Iksuda Therapeutics | 03/08/2026 | By News Bureau
Iksuda Therapeutics Secures FDA IND Clearance for IKS014
Iksuda Therapeutics has received FDA clearance for its IND application for IKS014, a HER2-targeting antibody drug conjugate, paving the way for US site participation in its ongoing Phase 1 trial for advanced HER2-positive solid tumours.
Iksuda Therapeutics | 02/07/2025 | By Mrinmoy Dey | 222
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy